BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 31649670)

  • 41. Graphene oxide polarizes iNKT cells for production of TGFβ and attenuates inflammation in an iNKT cell-mediated sepsis model.
    Lee SW; Park HJ; Van Kaer L; Hong S; Hong S
    Sci Rep; 2018 Jul; 8(1):10081. PubMed ID: 29973666
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The interface between innate and acquired immunity: glycolipid antigen presentation by CD1d-expressing dendritic cells to NKT cells induces the differentiation of antigen-specific cytotoxic T lymphocytes.
    Nishimura T; Kitamura H; Iwakabe K; Yahata T; Ohta A; Sato M; Takeda K; Okumura K; Van Kaer L; Kawano T; Taniguchi M; Nakui M; Sekimoto M; Koda T
    Int Immunol; 2000 Jul; 12(7):987-94. PubMed ID: 10882410
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Expression of CD1c enhances human invariant NKT cell activation by α-GalCer.
    Fox LM; Miksanek J; May NA; Scharf L; Lockridge JL; Veerapen N; Besra GS; Adams EJ; Hudson AW; Gumperz JE
    Cancer Immun; 2013; 13():9. PubMed ID: 23885215
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Anti-Vα24Jα18 TCR Antibody Tunes iNKT Cell Responses to Target and Kill CD1d-negative Tumors in an FcγRII (CD32)-dependent Manner.
    Takami M; Aoki T; Nishimura K; Tanaka H; Onodera A; Motohashi S
    Cancer Res Commun; 2024 Feb; 4(2):446-459. PubMed ID: 38319156
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Poly(I:C) promotes the production of IL-17A by murine CD1d-driven invariant NKT cells in airway inflammation.
    Vultaggio A; Nencini F; Pratesi S; Petroni G; Romagnani S; Maggi E
    Allergy; 2012 Oct; 67(10):1223-32. PubMed ID: 22882449
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Administration of anti-CD25 mAb leads to impaired α-galactosylceramide-mediated induction of IFN-γ production in a murine model.
    Rosalia RA; Štěpánek I; Polláková V; Šímová J; Bieblová J; Indrová M; Moravcová S; Přibylová H; Bontkes HJ; Bubeník J; Sparwasser T; Reiniš M
    Immunobiology; 2013 Jun; 218(6):851-9. PubMed ID: 23182710
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Expansion of invariant natural killer T cells from systemic lupus erythematosus patients by alpha-Galactosylceramide and IL-15.
    Hsu CY; Chueh YS; Kuo ML; Lee PT; Hsiao HS; Huang JL; Lin SJ
    PLoS One; 2021; 16(12):e0261727. PubMed ID: 34936686
    [TBL] [Abstract][Full Text] [Related]  

  • 48. CD1d-independent activation of mouse and human iNKT cells by bacterial superantigens.
    Hayworth JL; Mazzuca DM; Maleki Vareki S; Welch I; McCormick JK; Haeryfar SM
    Immunol Cell Biol; 2012 Aug; 90(7):699-709. PubMed ID: 22041925
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Exploiting the CD1d-iNKT cell axis for potentiation of DC-based cancer vaccines.
    Lameris R; Schneiders FL; de Gruijl TD; van der Vliet HJ
    Methods Mol Biol; 2014; 1139():155-65. PubMed ID: 24619678
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Recognition of β-linked self glycolipids mediated by natural killer T cell antigen receptors.
    Pellicci DG; Clarke AJ; Patel O; Mallevaey T; Beddoe T; Le Nours J; Uldrich AP; McCluskey J; Besra GS; Porcelli SA; Gapin L; Godfrey DI; Rossjohn J
    Nat Immunol; 2011 Jul; 12(9):827-33. PubMed ID: 21804559
    [TBL] [Abstract][Full Text] [Related]  

  • 51. NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells.
    Hermans IF; Silk JD; Gileadi U; Salio M; Mathew B; Ritter G; Schmidt R; Harris AL; Old L; Cerundolo V
    J Immunol; 2003 Nov; 171(10):5140-7. PubMed ID: 14607913
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunomodulatory Functions of α-GalCer and a Derivative, α-Carba-GalCer.
    Satoh M; Iwabuchi K
    Methods Mol Biol; 2023; 2613():1-11. PubMed ID: 36587066
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Invariant TCR rather than CD1d shapes the preferential activities of C-glycoside analogues against human versus murine invariant NKT cells.
    Li X; Shiratsuchi T; Chen G; Dellabona P; Casorati G; Franck RW; Tsuji M
    J Immunol; 2009 Oct; 183(7):4415-21. PubMed ID: 19734232
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antigen specificity of semi-invariant CD1d-restricted T cell receptors: the best of both worlds?
    Gumperz JE
    Immunol Cell Biol; 2004 Jun; 82(3):285-94. PubMed ID: 15186260
    [TBL] [Abstract][Full Text] [Related]  

  • 55. α-Galactosylceramide treatment before allergen sensitization promotes iNKT cell-mediated induction of Treg cells, preventing Th2 cell responses in murine asthma.
    Chen Q; Guo X; Deng N; Liu L; Chen S; Wang A; Li R; Huang Y; Ding X; Yu H; Hu S; Nie H
    J Biol Chem; 2019 Apr; 294(14):5438-5455. PubMed ID: 30745361
    [TBL] [Abstract][Full Text] [Related]  

  • 56. α-Galactosylceramide-induced airway eosinophilia is mediated through the activation of NKT cells.
    Chuang YH; Wang TC; Jen HY; Yu AL; Chiang BL
    J Immunol; 2011 Apr; 186(8):4687-92. PubMed ID: 21383248
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Structural evaluation of potent NKT cell agonists: implications for design of novel stimulatory ligands.
    Schiefner A; Fujio M; Wu D; Wong CH; Wilson IA
    J Mol Biol; 2009 Nov; 394(1):71-82. PubMed ID: 19732779
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Structural and functional characterization of a novel nonglycosidic type I NKT agonist with immunomodulatory properties.
    Kerzerho J; Yu ED; Barra CM; Alari-Pahissa E; Girardi E; Harrak Y; Lauzurica P; Llebaria A; Zajonc DM; Akbari O; Castaño AR
    J Immunol; 2012 Mar; 188(5):2254-65. PubMed ID: 22301545
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Species-specific activity of glycolipid ligands for invariant NKT cells.
    Dangerfield EM; Cheng JM; Knight DA; Weinkove R; Dunbar PR; Hermans IF; Timmer MS; Stocker BL
    Chembiochem; 2012 Jun; 13(9):1349-56. PubMed ID: 22639457
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Mouse and human iNKT cell agonist β-mannosylceramide reveals a distinct mechanism of tumor immunity.
    O'Konek JJ; Illarionov P; Khursigara DS; Ambrosino E; Izhak L; Castillo BF; Raju R; Khalili M; Kim HY; Howell AR; Besra GS; Porcelli SA; Berzofsky JA; Terabe M
    J Clin Invest; 2011 Feb; 121(2):683-94. PubMed ID: 21245578
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.